Categories: BrainMedicareNews

Relievant Medsystems Announces Positive Local Coverage Determination by Palmetto GBA for Basivertebral Nerve Ablation in Treating Chronic Vertebrogenic Low Back Pain

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

MINNEAPOLIS, March 06, 2023 (GLOBE NEWSWIRE) — Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic pain, a type of chronic low back pain (CLBP), today announced that Palmetto GBA has published a final Local Coverage Determination (LCD) for basivertebral nerve (BVN) ablation that expands access to more than 5 million covered lives.

Palmetto GBA is a Medicare Administrative Contractor (MAC) covering Medicare patients in Alabama, Georgia, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia. The formal LCD went into effect on March 5, 2023.

“This LCD represents a significant step in increasing access to BVN ablation – both for patients suffering from chronic vertebrogenic low back pain as well as the physicians working to treat them effectively,” said Tyler Binney, President and CEO of Relievant Medsystems. “We are pleased that Palmetto GBA recognized the strong clinical evidence supporting the Intracept Procedure and we remain dedicated to educating payers about the life-changing outcomes of this therapy.”

Relievant Medsystems’ minimally invasive Intracept® Procedure is the only FDA-cleared treatment for chronic vertebrogenic low back pain, using targeted radiofrequency energy to stop the BVN from transmitting pain signals to the brain. The procedure is typically performed in an outpatient surgery center and takes approximately one hour. Based on existing data, patients typically experience minimal post-procedure pain and generally quick recovery times. Patients often feel pain relief within two weeks of being treated with the Intracept Procedure.

About Vertebrogenic Pain
Of the 30 million people in the U.S. with chronic low back pain, 1 in 6 are likely to have vertebrogenic pain, a distinct type of chronic low back pain caused by damage to vertebral endplates, the interface between the disc and the vertebral body. Patients typically have pain in the middle of their low back, which worsens when they bend over, sit for long periods of time, or when they are active. A physician can confirm a patient’s pain is vertebrogenic by observing Modic changes, a biomarker seen on standard MRI that indicates inflammation at the vertebral endplate.

About Relievant Medsystems
Relievant Medsystems is a commercial-stage medical device company transforming the diagnosis and treatment of vertebrogenic pain, a form of Chronic Low Back Pain (CLBP), with the Intracept Procedure – a novel, clinically proven and commercially available treatment designed to improve the quality of life for millions of indicated patients. For more information about Relievant Medsystems and the Intracept Procedure, visit www.relievant.com.

Media Contact:
Shelli Lissick, Bellmont Partners
(651) 276-6922 | shelli@bellmontpartners.com

Investor Contact:
Marissa Bych, Gilmartin Group
(805) 305-1244 | marissa@gilmartinir.com

Staff

Recent Posts

Bay Area Cognitive Behavioral Therapy Center Expands Treatment Offerings with Acceptance and Commitment Therapy

Bay Area Therapy Center Expand Treatment Options Offering Comprehensive Mental Health Services in San FranciscoSAN…

20 hours ago

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease New…

20 hours ago

Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance

The Company is withdrawing current submission based on FDA feedback related to shelf-life stability of…

1 day ago

ZEISS Shapes the Future of Metrology with Cutting-Edge Technologies Revealed at Event

ZEISS Industrial Quality Solutions will host its first-ever digital launch event for the USA and…

1 day ago

The OhmX RAMP UP Grant Awarded to 15 Laboratories to Advance Genomic Research

PROVIDENCE, R.I., Feb. 21, 2025 /PRNewswire/ -- Nabsys 2.0, LLC (Nabsys) and Hitachi High-Tech America,…

2 days ago